Pioneering the next generation of drug discovery
Prediction to patient
It isn’t effective to start with a single target in mind.
Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery programme. Our AI platform overcomes these challenges by analysing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, we can run multiple stages in parallel and at scale.
This isn't traditional drug discovery
One disease, one target, one drug: it's an overly simple model, yet it's the one used by nearly all pharmaceutical companies.
The next generation of drug discovery is AI-powered, parallel and hypothesis-free. Bringing together the key three drug discovery paradigms.
Biomedical literature and other texts
Curated biological disease data
Commercial and biochemical information
years of reading
Orphan drug designations
Compound gene associations
in vitro/ in vivo models
AI-reasoning predictions and knowledge graph to identify novel disease-compound relationships
Drug discovery expert analysis
These predictions are reviewed by our team of experts and progressed to lab testing.